Zum Inhalt springen

The Evidence Base

@theevidencebase.bsky.social did:plc:pb4wpto3rgocga55xxqs6ecg

Providing the latest news, opinion and insight into hot topics including real-world data, health economics and outcomes research and patient-centric care.

Bei Bluesky seit

Follower
119
Folgt
72
Posts
608
Tage in Ranglisten
0

Zusammenfassung

The Evidence Base (@theevidencebase.bsky.social) ist seit 6 Dezember 2024 auf Bluesky. Das Konto hat 119 Follower, folgt 72 Konten und hat 608 Posts veröffentlicht.

Ranglisten-Platzierungen

Die besten Tage, an denen Posts dieses Kontos in Debyas Tagesliste kamen.

Dieses Konto war noch in keiner Tagesrangliste.

Zuletzt gelikte Posts

Öffentliche Likes aus dem Bluesky-Netzwerk.

  • Journal of Comparative Effectiveness Research@journal-cer.bsky.social

    📢New article alert Treatment burden and healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps who did or did not undergo functional endoscopic sinus surgery: a US real-world retrospective cohort study 🔗 becarispublishing.com/doi/10.57264... #OpenAccess #JCER

    Post anzeigen
  • Journal of Comparative Effectiveness Research@journal-cer.bsky.social

    📢New article alert New Perspective article on "Sieving for gold: external comparator studies to prioritize drugs for late-stage clinical trial" 🔗Read here: becarispublishing.com/doi/10.57264... #OpenAccess #JCER #TrialMethodology #RealWorldEvidence #RWE

    Post anzeigen
  • Journal of Comparative Effectiveness Research@journal-cer.bsky.social

    📢New article alert New Research Article on “Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2–positive metastatic colorectal cancer”. 🔗Read here: becarispublishing.com/doi/10.57264... #OpenAccess #JCER #ColorectalCancer #Oncology #ITC

    Post anzeigen
  • Journal of Comparative Effectiveness Research@journal-cer.bsky.social

    📢New Research Article alert "Acthar Gel versus standard of care for adults with proteinuria in nephrotic syndrome due to focal segmental glomerulosclerosis: cost-per-response analysis from the US healthcare perspective" 🔗 becarispublishing.com/doi/10.57264... #OpenAccess #JCER #KidneyDisease

    Post anzeigen
  • Journal of Comparative Effectiveness Research@journal-cer.bsky.social

    📢New article alert New Short Report on "First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis". 🔗Read here: becarispublishing.com/doi/10.57264... #OpenAccess

    Post anzeigen

Melde dich an, um mehr zu sehen

Blockierte Konten

Blockierungen sind auf Bluesky öffentlich.

Dieses Konto blockiert niemanden.